{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:41:57Z","timestamp":1767890517437,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12185-022-03474-x","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T09:03:54Z","timestamp":1671095034000},"page":"216-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma"],"prefix":"10.1007","volume":"117","author":[{"given":"Jongheon","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Yoon","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Hee","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"9","key":"3474_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","volume":"23","author":"K Laribi","year":"2018","unstructured":"Laribi K, Alani M, Truong C, de Materre AB. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018;23(9):1039\u201353. https:\/\/doi.org\/10.1634\/theoncologist.2017-0524.","journal-title":"Oncologist"},{"issue":"2","key":"3474_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bmt.2009.165","volume":"45","author":"A Numata","year":"2010","unstructured":"Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45(2):311\u20136. https:\/\/doi.org\/10.1038\/bmt.2009.165.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3474_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176(6):851\u201366. https:\/\/doi.org\/10.1111\/bjh.14473.","journal-title":"Br J Haematol"},{"issue":"12","key":"3474_CR4","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008;111(12):5496\u2013504. https:\/\/doi.org\/10.1182\/blood-2008-01-134270.","journal-title":"Blood"},{"issue":"12","key":"3474_CR5","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402\u20138. https:\/\/doi.org\/10.1182\/blood-2010-09-310342.","journal-title":"Blood"},{"issue":"4","key":"3474_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11899-010-0062-x","volume":"5","author":"PP Piccaluga","year":"2010","unstructured":"Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, et al. Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 2010;5(4):222\u20138. https:\/\/doi.org\/10.1007\/s11899-010-0062-x.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"3474_CR7","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139. https:\/\/doi.org\/10.1182\/blood-2003-09-3080.","journal-title":"Blood"},{"issue":"6","key":"3474_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.15258","volume":"181","author":"M Federico","year":"2018","unstructured":"Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the international T cell project network. Br J Haematol. 2018;181(6):760\u20139. https:\/\/doi.org\/10.1111\/bjh.15258.","journal-title":"Br J Haematol"},{"key":"3474_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.2147\/OTT.S137002","volume":"10","author":"HJ Xu","year":"2017","unstructured":"Xu HJ, Ma Y, Deng F, Ju WB, Sun XY, Wang H. The prognostic value of C-reactive protein\/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther. 2017;10:3059\u201370. https:\/\/doi.org\/10.2147\/OTT.S137002.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3474_CR10","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41598-021-82087-6","volume":"11","author":"J Jung","year":"2021","unstructured":"Jung J, Lee H, Heo JH, Chang MH, Lee E, Park WS, et al. High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma. Sci Rep. 2021;11(1):2674. https:\/\/doi.org\/10.1038\/s41598-021-82087-6.","journal-title":"Sci Rep"},{"issue":"2","key":"3474_CR11","doi-asserted-by":"publisher","first-page":"155932582091782","DOI":"10.1177\/1559325820917824","volume":"18","author":"QS Di","year":"2020","unstructured":"Di QS, Xu T, Song Y, Zuo ZG, Cao FJ, Yu XJ, et al. High C-reactive protein to albumin ratio predicts inferior clinical outcomes in extranodal natural killer T-cell lymphoma. Dose Response. 2020;18(2):1559325820917824. https:\/\/doi.org\/10.1177\/1559325820917824.","journal-title":"Dose Response"},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3389\/fonc.2019.01392","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Guo X, Hao J, Dong Y, Zhang T, Ma X. The prognostic value of blood-based biomarkers in patients with testicular diffuse large B-cell lymphoma. Front Oncol. 2019;9:1392. https:\/\/doi.org\/10.3389\/fonc.2019.01392.","journal-title":"Front Oncol"},{"key":"3474_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12935-018-0609-9","volume":"18","author":"S Mu","year":"2018","unstructured":"Mu S, Ai L, Fan F, Qin Y, Sun C, Hu Y. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis. Cancer Cell Int. 2018;18:119. https:\/\/doi.org\/10.1186\/s12935-018-0609-9.","journal-title":"Cancer Cell Int"},{"issue":"27","key":"3474_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3474_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BF, Gy\u0151rffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12): e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862.","journal-title":"PLoS ONE"},{"issue":"6","key":"3474_CR16","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16263","volume":"188","author":"L Bento","year":"2020","unstructured":"Bento L, D\u00edaz-L\u00f3pez A, Barranco G, Mart\u00edn-Morena AM, Baile M, Mart\u00edn A, et al. New prognosis score including absolute lymphocyte\/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish lymphoma group experience (GELTAMO). Br J Haematol. 2020;188(6):888\u201397. https:\/\/doi.org\/10.1111\/bjh.16263.","journal-title":"Br J Haematol"},{"issue":"43","key":"3474_CR17","doi-asserted-by":"publisher","first-page":"74975","DOI":"10.18632\/oncotarget.20480","volume":"8","author":"J Jung","year":"2017","unstructured":"Jung J, Lee H, Yun T, Lee E, Moon H, Joo J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Oncotarget. 2017;8(43):74975\u201386. https:\/\/doi.org\/10.18632\/oncotarget.20480.","journal-title":"Oncotarget"},{"key":"3474_CR18","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.1742","volume":"4","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang L, Zhang WW, Yan SM, Sun P, Xia Y, et al. The pretreatment albumin to globulin ratio predicts survival in patients with natural killer\/T-cell lymphoma. PeerJ. 2016;4: e1742. https:\/\/doi.org\/10.7717\/peerj.1742.","journal-title":"PeerJ"},{"issue":"3","key":"3474_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/10428194.2019.1700244","volume":"61","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shi Y, Shen H, Zhou D, Li L, Zhu J, et al. The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma. Leuk Lymphoma. 2020;61(3):623\u201330. https:\/\/doi.org\/10.1080\/10428194.2019.1700244.","journal-title":"Leuk Lymphoma"},{"key":"3474_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https:\/\/doi.org\/10.3389\/fimmu.2018.00754.","journal-title":"Front Immunol"},{"issue":"4","key":"3474_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/10408363.2011.599831","volume":"48","author":"KH Allin","year":"2011","unstructured":"Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155\u201370. https:\/\/doi.org\/10.3109\/10408363.2011.599831.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"6","key":"3474_CR22","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1016\/j.clgc.2018.07.027","volume":"16","author":"T Nakayama","year":"2018","unstructured":"Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151\u20138. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.027.","journal-title":"Clin Genitourin Cancer"},{"key":"3474_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejim.2018.04.014","volume":"52","author":"S Arques","year":"2018","unstructured":"Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018;52:8\u201312. https:\/\/doi.org\/10.1016\/j.ejim.2018.04.014.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"3474_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2019.10.031","volume":"133","author":"A Eckart","year":"2020","unstructured":"Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurfluh S, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. Am J Med. 2020;133(6):713-22.e7. https:\/\/doi.org\/10.1016\/j.amjmed.2019.10.031.","journal-title":"Am J Med"},{"issue":"1","key":"3474_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1172\/JCI114419","volume":"85","author":"DA Brenner","year":"1990","unstructured":"Brenner DA, Buck M, Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest. 1990;85(1):248\u201355. https:\/\/doi.org\/10.1172\/JCI114419.","journal-title":"J Clin Invest"},{"issue":"5","key":"3474_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12185-020-02818-9","volume":"111","author":"Y Wei","year":"2020","unstructured":"Wei Y, Wei X, Huang W, Song J, Zheng J, Zeng H, et al. Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. Int J Hematol. 2020;111(5):681\u20135. https:\/\/doi.org\/10.1007\/s12185-020-02818-9.","journal-title":"Int J Hematol"},{"key":"3474_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2018.02.003","volume":"64","author":"D Boakye","year":"2018","unstructured":"Boakye D, Rillmann B, Walter V, Jansen L, Hoffmeister M, Brenner H. Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis. Cancer Treat Rev. 2018;64:30\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.003.","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"3474_CR28","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.03.6327.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"3474_CR29","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1080\/10428190310001623775","volume":"44","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):S41\u20137. https:\/\/doi.org\/10.1080\/10428190310001623775.","journal-title":"Leuk Lymphoma"},{"issue":"10168","key":"3474_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03474-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T17:01:51Z","timestamp":1675184511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03474-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) (National Cancer Center 2020-0110, National Health Insurance Service Ilsan Hospital 2020-04-020) and complied with the Declaration of Helsinki. The requirement for informed consent was waived by the IRB, considering that no intervention was involved due to the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}